Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer

Inclusion Criteria:

• > 18 year olds

• Eligibility checklist before registration requires review of case by study surgeonor interventional pulmonologists to approve anatomic feasibility of an airwayintervention

• For patients in Cohort B only. Patients are amenable to receive a palliativeradiotherapy of 8 Gy x1 48±4 h prior to the I-PDT, as determined by the radiationoncologist

• Patients with an established pathologic diagnosis of small cell and/or non-smallcell lung cancer or other malignancies causing airway obstruction > 25% requiringbronchoscopic intervention. Or inoperable malignancies not candidates for curativeradiotherapy within the airway.

• Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 3

• Platelets >= 100,000 cells/mm^3 (International System of Units [SI] units 100 x 10^9/L).

• Participants of child-bearing potential must agree to use adequate contraceptivemethods (e.g., hormonal or barrier method of birth control; abstinence) prior tostudy entry. Should a woman become pregnant or suspect she is pregnant while she orher partner is participating in this study, she should inform her treating physicianimmediately.

• Participant must understand the investigational nature of this study and sign anIndependent Ethics Committee/Institutional Review Board approved written informedconsent form prior to receiving any study related procedure.

Exclusion Criteria:

• Participants who have had radiotherapy to the target tumor within 4 weeks prior tothe scheduled I-PDT and/or PDT.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or activeinfection, symptomatic congestive heart failure, unstable angina pectoris, cardiacarrhythmia, or psychiatric illness/social situations that would limit compliancewith study requirements.

• Pregnant or nursing female participants.

• Co-existing ophthalmic disease likely to require slit-lamp examination within 14days following I-PDT and/or PDT treatment.

• Known hypersensitivity/allergy to porphyrin.

• Patients who are not cleared by the anesthesiologist to undergo an advancedbronchoscopy procedure under general anesthesia.

• Patients with target tumor invading into the lumen of the esophagus, confirmed byesophago-gastro-duodenoscopy (EGD) with endoscopic ultrasound

• Patients diagnosed with porphyria.

• Unwilling or unable to follow protocol requirements.

• Any condition which in the Investigator's opinion deems the participant anunsuitable candidate to receive I-PDT or PDT.